AbbVie to Showcase Research at AAD 2019

AbbVie announces it will present 19 abstracts during the 2019 American Academy of Dermatology (AAD) Annual Meeting, March 1-5, in Washington, DC, including new data from the psoriasis pivotal trials for risankizumab, an investigational interleukin-23 (IL-23) inhibitor.